Australian data in global surveillance of population-based cancer survival (the CONCORD programme) (#262)
Global cancer survival comparisons, including with Australia, are difficult due to differences in data collection, analysis and reporting, limiting clinical interpretation of cancer survival data. The CONCORD programme will establish global surveillance of cancer survival, with centralised quality control and analysis, and will provide standardised outcome metrics for comparison of the overall effectiveness of health systems.
Data are expected for 30 million adult patients (15-99 years) diagnosed during 1995-2009 with one of 10 malignancies: breast, cervix, colon, liver, lung, ovary, prostate, rectum and stomach cancer leukaemia. Net survival will be estimated, corrected for background mortality by single year of age, sex, calendar year (and race, ethnicity or indigenous status) in each country or region. Survival will be age-standardised with the International Cancer Survival Standard weights. Population “cure” and avoidable premature mortality will be estimated.
As of 17 July 2013, 279 population-based cancer registries, including 5 Australian states, had registered to participate. We have received 1,920 data sets from 211 registries. More data sets are still arriving. The first phase of quality control has been completed on 1,840 data sets from 203 (96%) registries, and reports have been sent to 197 (97%) of those registries. The remaining 80 data sets from 8 registries were not viable for quality control and the registries are preparing to resubmit them. In some registries, the data sets are ready for transmission, but ethical approval processes are not yet complete. We will present global and Australian-specific data calculated to date.
Robust comparisons of survival trends and inequalities will prompt improvement of national health systems.
Canadian Partnership Against Cancer (Toronto); Cancer Focus Northern Ireland (Belfast); Cancer Institute New South Wales (Sydney); Cancer Research UK (London); Centers for Disease Control and Prevention (Atlanta); Children with Cancer UK (London); Istituto Superiore di Sanità (Rome); Swiss Cancer League; Swiss Cancer Research foundation; Swiss Re (London); University of Kentucky (Lexington)